Anthera Pharmaceuticals Inc. was soaring late Tuesday after saying it has promoted J. Craig Thompson to chief executive officer at the drugmaker, replacing Paul Truex ahead of the company completing its commercialization efforts for its Sollpura pancreatic enzyme replacement product candidate.
Thompson also will join the Anthera board as a director while Truex will become executive board chairman when Christopher Henny, the current board chairman, steps aside but remains a member on the board.
Separately, the company tonight reported positive trends for its blisibimod drug candidate following 48 weeks of proof-of-concept testing in patients with IgA nephropathy. According to the company, the blisibimod treated-patients over time demonstrated stable to slightly decreasing estimated levels of urinary protein excretion compared wide slowly rising levels of proteinuria in the placebo group.
No problems with safety or tolerability were observed with blisibimod during routine reviews of the unblinded trial data by the trials independent data and safety monitoring board. Data from the study will be submitted and presented at an upcoming scientific conference, the company said.